Here are the DEF 14A proxy statements from BriaCell Therapeutics Corp. Warrant (BCTXZ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BCTXZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTXZ filings page.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.